Jubilant Life Sciences jumped 5.3 per centum to Rs 671.40 on BSE afterward the companionship announced signing of long term contracts inward radiopharma business.
The annunciation was made during marketplace seat hours today, four Jan 2017.
Meanwhile, the BSE Sensex was upward 40.20 points, or 0.15 percent, to 26,683.44.
On the BSE, 90,238 shares were traded inward the counter thence far, compared amongst average daily volumes of 1.29 lakh shares inward the past times ane quarter. The stock had hitting a high of Rs 674 together with a depression of Rs 638 thence far during the day.
The stock had hitting a tape high of Rs 726.40 on 1 Dec 2016. The stock had hitting a 52-week depression of Rs 272.50 on twenty Jan 2016. The stock had underperformed the marketplace seat over the past times ane calendar month till iii Jan 2017, falling 7.75 per centum compared amongst the 1.57 per centum ascension inward the Sensex. The scrip had, however, outperformed the marketplace seat inward past times ane quarter, declining 2.3 per centum every bit against Sensex's 5.67 per centum decline.
The large-cap companionship has equity upper-case missive of the alphabet of Rs 15.93 crore. Face value per portion is Re 1.
Jubilant Life Sciences announced that its wholly ain subsidiary, Jubilant Pharma, through ane of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts amongst distribution networks inward the US.
The contracts are for the furnish of products used for diagnostic together with therapeutic procedures for thyroid, myocardial perfusion, lung, kidney together with bone scans to live on supplied past times JDI over a menses of 39 months effective from Jan 2017.
Commenting on the occasion, Shyam S. Bhartia, Chairman together with Hari S. Bhartia, Co-Chairman together with Managing Director, Jubilant Life Sciences said that these contracts provide visibility on company's hereafter revenues amongst the differentiated together with niche products inward specialty pharma describe concern together with will strengthen the companionship for its growth, going forward.
On a consolidated basis, cyberspace turn a profit of Jubilant Life Sciences rose 14.5 per centum to Rs 144.77 crore on 5.2 per centum turn down inward cyberspace sales to Rs 1359.70 crore inward Q2 September 2016 over Q2 September 2015.
Jubilant Life Sciences is an integrated global pharmaceutical together with life sciences companionship engaged inward pharmaceuticals, life scientific discipline ingredients and drug regain solutions.
Capitalstars Financial Research Private Limited is a inquiry describe solid together with an investment advisory carrying out operations inward the Indian Equities together with Commodity market.We every bit good provide 2 days complimentary trial to our client.Join our services together with merchandise amongst us.
* Investment & trading inward securities marketplace seat is ever subjected to marketplace seat risks, past times performance is non a guarantee of hereafter performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
